X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Brave new world - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Dec 20, 2002

    Pharma: Brave new world

    The pharma sector majors continue on their journey to infinity and beyond. The revenue model adopted by these companies is perhaps the boldest in the Indian industry. These companies are following a two-pronged approach. First approach is weaved around looking for an opportunity to tap an existing patent viz. challenge the patent of existing products or wait for the patent to expire and then launch the generic version to tap US market.

    The second revenue stream is an even bolder one. These companies plan to offer research and development (R&D) services to global majors or carry out work on their own. Considering, the expenditure required for experimentation and the fact that years of research could lead to disappointment makes the bet a very risk one.

    The generics front
    In August 2001, Dr. Reddy's won the challenge to the patent on fluoxetine (generic of Eli Lilly's block buster product Prozac) and the right to launch the drug. It got a 180-day marketing exclusivity for fluoxetine. Consequently, the generics business, which started with modest sales in 1QFY02, ended the year (fiscal FY02) with 26% of the company's turnover. This was mainly fuelled by fluoxetine 40 mg capsules contributing around 21% to the total turnover of the company i.e. Rs 3,286 m (US$ 67 m). However, since the marketing exclusivity for fluoxetine expired in January '02, two other competitors have entered the market. This has led to a sharp price erosion (almost 80%) for the drug.

    In February 2002, Ranbaxy received FDA approval for marketing Cefuroxime Axetil tablets in the US markets after a long legal battle and launched the drug in March 2002. Ceftum (generic Cefuroxime) had already gone off patent in 2000. Due to lack of any other player in the market with necessary approvals, Ranbaxy continues to enjoy ‘technical’ monopoly (in generic version) for marketing this anti-infective in the US markets. Post its launch, the company has already enjoyed about 9 months of exclusivity on the US$ 400 m drug and this exclusivity is likely to continue for some months into the future. Apotex, the nearest generic competitor of Ranbaxy recently received the US FDA approval for its ANDA of Cefuroxime Axetil (only for certain dosages). But Apotex is unlikely to launch its product due to its pending litigation on patent infringement and marketing injunction filed by original patent holder Glaxo.

    In the recent past the industry has had its share of disappointments. In November 2001, Dr. Reddy’s lost its challenge to the patent on Omeprazole (an anti-ulcerant product) the largest selling pharma product in the world with US sales in excess of US$ 4 bn. In October 2002, Andrx, the US partner of Cipla, lost the patent infringement case against the original patent holder, AstraZeneca.

    The research front
    On the research front, Indian pharma majors have been working on molecules and further licensing them to global pharma MNCs. While Ranbaxy became the first company to license a new once–a–day dosage form of ciprofloxacin to Bayer (Novel Drug Discovery System), Dr. Reddy was the first to license a New Chemical Entity (NCE), an anti–diabetes molecule to Novo Nordisk of Denmark.

    The disappointments have not been limited to the generics business. In July 2002, clinical trials for Dr. Reddy’s anti-diabetic molecule DRF-2725 licensed to Novo Nordisk were suspended. This came as a major setback for the company. DRF-2725, the dual acting insulin sensitiser termed as ‘Ragaglitazar’ was counted among the major catalysts for the company’s research efforts.

    Recent developments
    Due to the disappointments in the recent past, pharma stocks have been out of favour. However, this week brought good news. Firstly, Bayer’s Cipro XR 500 mg got approval from the US FDA (foods and drug authority). This was a positive for Ranbaxy as it has worked on the drug delivery system of this product. The drug delivery system has been licensed out to Bayer for a consideration of US$ 65 m. Of this, Ranbaxy has already received US$ 22 m. Once the product is launched in the market (January 2003) the royalty will start to flow in (6%-8% of sales). With sales of Cipro expected to be in the range of US$ 300 m, Ranbaxy could earn as much as US$ 15 m.

    In another development, the US courts ruled in favour of Dr. Reddy’s in the Amlodiphine Malate patent. Consequently, the company will be able to launch the product by August next year, when Pfizer's exclusivity term on the product expires. This however, is subject to Dr. Reddy’s winning a citizen's petition that Pfizer has filed with FDA seeking to deny the recent approval. If the company wins this battle, this could translate in significant revenues for Dr. Reddy’s. The original patented drug of Pfizer, Norvasc has sales in excess of US$ 1.7 bn.

              52 week P/E (x) range
    Company FY03E EPS
    (Rs )
    CMP
    (Rs)
    52 week
    high /low (Rs)
    Current
    P/E (x)
    High Low
    Dr. Reddy's 61.2 907 1,149 / 676 14.8 18.8 11.0
    Cipla 55.5 891 1,029 / 806 16.1 18.5 14.5
    Ranbaxy 31.8 567 590 / 412 17.8 18.6 13.0

    Currently almost all domestic pharma majors are trading at lower levels compared to their historic valuations. Also a series of successes in generics and R&D business could cause a re-rating of the sector. Therefore, this could be an opportunity to make investments in the sector considering a long-term perspective. However, please be aware of the pitfalls of treading the generics or the R&D strategy.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: Brave new world". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 23, 2017 03:36 PM

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS